Grifols (GIFLF) Receivables - Net (2010 - 2025)
Grifols (GIFLF) reported Receivables - Net of $895.1 million for Q4 2025, up 18.82% on a YoY basis from $753.4 million in Q4 2024, and up 18.82% quarter-over-quarter from $753.4 million in Q4 2024.
Grifols (GIFLF) Receivables - Net (2010 - 2025) Analysis & Trends
Grifols has reported Receivables - Net for 16 years, with the latest figure at $895.1 million in Q4 2025.
- For the quarter ending Q4 2025, Receivables - Net rose 18.82% year-over-year to $895.1 million; the trailing twelve-month figure through Dec 2025 stood at $895.1 million (up 18.82% YoY), and the FY2025 full-year result was $895.1 million, up 18.82% from the prior year.
- Receivables - Net for Q4 2025 stood at $895.1 million, up from $753.4 million in the prior quarter.
- The five-year high for Receivables - Net was $895.1 million in Q4 2025, with the low at $496.6 million in Q4 2021.
- Historically, Receivables - Net has averaged $744.9 million across 5 years, with a median of $754.0 million in 2022.
- Annual changes were most pronounced in 2022 — Receivables - Net surged 51.82% — and 2024, when it retreated 8.74%.
- Grifols' Receivables - Net stood at $496.6 million in 2021, then surged by 51.82% to $754.0 million in 2022, then rose by 9.48% to $825.5 million in 2023, then dropped by 8.74% to $753.4 million in 2024, then rose by 18.82% to $895.1 million in 2025.
- The last three Receivables - Net figures came in at $895.1 million (Q4 2025), $753.4 million (Q4 2024), and $825.5 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 895.15 Mn |
| Dec 31, 2025 | 895.15 Mn |
| Dec 31, 2024 | 753.36 Mn |
| Dec 31, 2024 | 753.36 Mn |
| Dec 31, 2023 | 825.52 Mn |
| Dec 31, 2023 | 825.52 Mn |
| Dec 31, 2022 | 754.01 Mn |
| Dec 31, 2022 | 754.01 Mn |
| Dec 31, 2021 | 496.64 Mn |
| Dec 31, 2021 | 496.64 Mn |
| Dec 31, 2020 | 456.92 Mn |
| Dec 31, 2020 | 456.92 Mn |
| Dec 31, 2019 | 409.32 Mn |
| Dec 31, 2019 | 409.32 Mn |
| Dec 31, 2018 | 307.23 Mn |
| Dec 31, 2018 | 307.23 Mn |
| Jun 30, 2018 | 366.66 Mn |
| Jun 30, 2018 | 366.66 Mn |
| Dec 31, 2017 | 336.98 Mn |
| Dec 31, 2017 | 336.98 Mn |